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Abstract
MYC and RUNX oncogenes each trigger p53‐mediated failsafe responses when
overexpressed in vitro and collaborate with p53 deficiency in vivo. However,
together they drive rapid onset lymphoma without mutational loss of p53. This
phenomenon was investigated further by transcriptomic analysis of premalignant
thymus from RUNX2/MYC transgenic mice. The distinctive contributions of MYC
and RUNX to transcriptional control were illustrated by differential enrichment of
canonical binding sites and gene ontology analyses. Pathway analysis revealed
signatures of MYC, CD3, and CD28 regulation indicative of activation and
proliferation, but also strong inhibition of cell death pathways. In silico analysis of
discordantly expressed genes revealed Tnfsrf8/CD30, Cish, and Il13 among relevant
targets for sustained proliferation and survival. Although TP53 mRNA and protein
levels were upregulated, its downstream targets in growth suppression and
apoptosis were largely unperturbed. Analysis of genes encoding p53 posttransla-
tional modifiers showed significant upregulation of three genes, Smyd2, Set, and
Prmt5. Overexpression of SMYD2 was validated in vivo but the functional analysis
was constrained by in vitro loss of p53 in RUNX2/MYC lymphoma cell lines.
However, an early role is suggested by the ability of SMYD2 to block senescence‐
like growth arrest induced by RUNX overexpression in primary fibroblasts.
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1 | INTRODUCTION
The oncogenic potential of RUNX2 was first discovered
through its identification as a target for transcriptional
activation in a retroviral mutagenesis screen in transgenic
mice overexpressing MYC in the T‐cell compartment
(CD2‐MYC).1 It was subsequently shown that any of the
three murine Runx family genes can be selected for
activation in this transgenic model,2-4 suggesting a redun-
dant oncogenic role for RUNX overexpression in the
context of MYC‐induced lymphoma. Consistent with this
hypothesis, transgenic mice over‐expressing MYC along
with either RUNX1 or RUNX2 display rapid onset of T or B‐
cell lymphomas.5,6 Furthermore, retroviral mutagenesis
screens in CD2‐RUNX2 mice identified both MYC and
MYCN as preferred targets for activation, indicating a strong
selection for co‐activation of both gene families as drivers of
lymphoma.7
The Runx genes have also been observed as preferred
targets for retroviral activation in Eμ‐Myc transgenic
models and in mice deficient in p53 or p19Arf/Cdkn2a,8 but
are rarely seen in end‐stage tumors of wild‐type mice. A
rationale for this selective targeting is that the Runx genes
operate as “conditional” oncogenes, inducing growth
arrest when activated in primary cells but driving tumor
development when combined with MYC overexpression
or loss of function of the p53 pathway.9 In support of this
hypothesis, overexpression of RUNX2 alone is growth
suppressive in early T‐cell development, blocking differ-
entiation and proliferation at the β‐selection stage, but
confers predisposition to lymphoma and collaborates
strongly with germ‐line inactivation of p53.7,10 Moreover,
ectopic expression of any of the RUNX family induces
senescence‐like growth arrest (SLGA) in primary mouse
or human fibroblasts through a process that depends on
the integrity of both the p19Arf/p53 and p16Cdkn2a/Rb
arms of the tumor suppressor response.11-14
The CD2‐MYC model also displays the phenomenon
of conditional oncogenesis, as these mice have a low
incidence of lymphoma development, and mice that
remain healthy display no detectable expression of the
transgene.15 Although the CD2 locus control region
(LCR) is active from the common lymphoid precursor
stage,16 spontaneous tumors in the CD2‐MYC model
display productive T‐cell receptor (TCR) rearrangement
and express CD3.15 Moreover, analysis of TCR β‐chain
usage in CD2‐MYC lymphomas suggests that autoreactive
cells may be selected.17
In light of the potent effect of p53 loss on both
CD2‐RUNX2 and CD2‐MYC lymphoma development, it
was surprising that the combination of both transgenes
led to the rapid development of tumors in which the p53
pathway appears to be intact.18 In support of this
interpretation, the wild‐type p53 allele is retained in
primary tumors in CD2‐RUNX2/CD2‐MYC/p53+/− mice,
but rapidly lost on in vitro culture of lymphoma cell
lines which also display de novo activation of the
p53‐repressed target p19Arf.18 Moreover, unlike sponta-
neous tumors in CD2‐MYCmice, CD2‐RUNX2/CD2‐MYC
early onset lymphoma cells display a low apoptotic index
along with immunoblastic morphology, indicating that
this potent oncogene combination overcomes the pro-
pensity of RUNX2 and MYC to induce, respectively,
growth arrest and apoptosis.18
The molecular mechanism of p53 “bypass” in this
context remains unexplained but is addressed in this
study where the combinatorial effect of MYC and RUNX2
was examined by transcriptome analysis of thymus
tissues from 10‐day old CD2‐MYC/CD2‐RUNX2 mice, in
which previous studies have shown a large polyclonal
expansion of premalignant cells.2,6,18,19 The combination
of MYC and RUNX2 orchestrates TCR downstream
responses in favor of survival and proliferation. More-
over, our findings indicate that p53 is upregulated but
functionally quiescent in prelymphoma cells, suggesting
that posttranslational control of the p53 activity is
important for potent MYC/RUNX oncogenic synergy.
2 | METHODS
2.1 | Cells, constructs, and retroviral
transductions
Animals were routinely monitored and killed when showing
signs of ill health in line with the UK Animals (Scientific
Procedures) Act, 1986. CD2‐MYC, CD2‐RUNX2, CD2‐MYC/
CD2‐RUNX2, and Runx2/MYC/p53+/− transgenic animals
and their maintenance were described previously.19 Litter-
mate‐matched genotype controls were used to control for
mouse strain. The GIMP cell lines were established by
culturing tumor cells arising from Runx2/MYC/p53+/− in
vitro. Retroviral transductions of primary murine embryo
fibroblasts (MEFs) were performed as described previously.12
The retroviral vectors were based on the pBabe plasmid
carrying the puromycin‐selectable marker. cDNA encom-
passing the complete coding sequence of SMYD2 and
SMYD5 was cloned into a GFP‐selectable MIGR1 expression
vector and used to transfect GP+E86 producer lines. Viral
supernatents were then collected and used to transduce
primary MEFs before sorting cells expressing GFP. RUNX1‐
GFP transductions were as previously described.5
2.2 | Microarray analysis
RNA was isolated and purified from the thymuses of
10‐day‐old wild‐type and CD2‐MYC/Runx2 transgenic
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mice as previously described.2 Microarray analysis was
based on a previously archived dataset (GEO accession
number GSE80254). Briefly, whole genome expression
profiling was performed using Affymetrix mouse Gene-
Chip microarrays (MoGene‐1) in triplicate as per the
manufacturer’s protocol (Affymetrix, UK). Data analysis
was carried out using Partek Genomics Suite (Partek Inc,
St. Louis, MO). After Robust Multichip Average
normalization20 with GC content pre‐background adjust-
ment, differential expression analysis was performed
using ANOVA. Multiple testing correction was per-
formed and “q‐value” cut‐offs selected21 with gene
changes of q < 0.05 considered significant. Graphical
representations of data were prepared using CLC
Genomics Workbench 4.2
2.3 | Cell proliferation and senescence
staining
The CellTiter‐Glo Luminescent Cell Viability Assay
was performed as per the manufacturer’s instructions.
Briefly, the CellTiter‐Glo assay reagents were prepared
according to the manufacturer’s protocol. Next, in a
white 96‐well plate (Nunc, Thermo Fischer Scientific),
25 µL of cell suspension was added along with 25 µL of
prepared CellTiter‐Glo reagent. Plates were then
incubated for 30 minutes at room temperature before
luciferase activity was determined using a lumin-
ometer. Growth curves were performed over 15 days
in triplicate using trypan blue as a vital stain, whereas
senescence‐associated beta galactosidase (SA‐β‐gal)
staining was assayed in parallel after 8 days, both as
described previously.12
2.4 | Western blots and antibodies
Preparation of protein extracts from whole cells or day
10 mouse thymus tissue was performed as described
previously.12 Samples equivalent to 30μg total protein
(Bio‐Rad protein assay) were resolved on 8%, 10%, or 17%
SDS‐polyacrylamide gels and transferred to enhanced
chemiluminescence (ECL; Amersham) nitrocellulose
membranes. The antibodies used were α‐p16INK4a,
α‐p21WAF1, α‐actin (sc‐1207, sc‐471, and sc‐1616, respectively;
Santa Cruz Biotechnology), α‐p19ARF (ab80; Abcam), α‐p53
and α‐SMYD2 (IC12 and D14H7, respectively; Cell Signaling
Technology). Western blots were developed using ECL
reagent according to the manufacturer’s protocol.
2.5 | Bioinformatic analyses
Microarray analysis was performed and significantly
changed genes were defined as described above.
Principal component analysis (PCA) was performed
in R using the base statistics functions then visualized
using the “Rgl” package. Transcription factor binding
site enrichment analysis for various gene subsets was
performed using the “Anchored Combination Site
Analysis tool” from the oPOSSUM 3.0 suite of tools for
anchored RUNX2/MYC binding (with MYC as the
anchoring site and RUNX as the anchored site), or the
“Single Site Analysis” tool for MYC or RUNX2 sites
individually, using default settings.22 Gene Ontology
analysis using DAVID was performed for the stated
gene lists using default settings. The Ingenuity Path-
way Analysis platform (IPA, Qiagen) was used to
perform pathway analysis by loading gene IDs, fold‐
changes, and q‐values from the stated gene lists, then
performing a core expression analysis using default
settings. Heatmaps, barcharts, Venn diagrams, and
scatterplots were produced using custom R scripts.
3 | RESULTS
3.1 | Premalignant thymus reveals a
co‐operative program of transcriptional
regulation by MYC and RUNX2
As reported previously and illustrated in Figure 1A,
CD2‐MYC/CD2‐Runx2 mice develop rapid onset thymic
lymphoma with complete penetrance whereas the
parental CD2‐Runx2 and CD2‐MYC strains display low
lifetime rates of tumor development.6 To explore further
the mechanism of this potent oncogene collaboration, we
analyzed early transcriptome changes in the thymus of
10‐day‐old CD2‐Runx2/CD2‐MYC mice. These mice
harbor a large premalignant population comprising a
thymocyte fraction that is 40%‐60% polyclonal, as
assessed by rearrangement of TCR β‐chain genes. This
premalignant phase precedes the development of oligo-
clonal end‐stage thymic lymphomas that disseminate to
peripheral lymphoid tissues and other organs at age 4 to 6
weeks.2,6,19 RNA samples extracted from 10‐day thymus
tissues were analyzed by Affymetrix gene expression
microarray (MoGene‐1) and compared with normal
controls from the same strain background (C57/CBA).2
Parental CD2‐MYC and CD2‐Runx2 strains were not
analyzed here as most 10‐day‐old CD2‐MYC mice display
no detectable transgene expression in thymus,15 whereas
CD2‐Runx2 mice at the same stage display only a small
abnormal population of CD8 ISP cells with low pro-
liferative capacity.10 The transcriptomic dataset was
deposited previously during our study of lymphoma
progression and retroviral mutagenesis2 but is used here
for the first time to address the mechanistic basis of the
MYC/RUNX2 oncogene collaboration.
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Principal Component Analysis demonstrated good
separation of the WT and RUNX2/MYC sample groups,
and showed a higher divergence between the transgenic
samples, indicative of increased polyclonality (Figure 1B).
The most significantly changed genes are illustrated in
the heat map shown in Figure 1C. As shown in Figure
1D, a q = < 0.05 cut‐off revealed a preponderance of
upregulated genes, with almost five times as many
significantly upregulated as downregulated genes (896
and 171 genes, respectively, from 1178 and 239 individual
up and downregulated probes, respectively; Table S1).
This bias towards upregulation was not observed in the
much larger dataset generated by a P=< .05 cut‐off, but
was restored by adding a filter for probe sets changed by
>1.5‐fold. This indicates that the major difference is in
the magnitude of changes in the upregulated set, and was
observed previously for MYC‐regulated genes during the
controversy over whether MYC acts as a “universal
amplifier” that upregulates virtually all expressed genes23
or as an on‐off regulator of key target genes in cancer
cells.24,25
To explore the roles of MYC and RUNX2 in
regulation, the genes meeting the q‐value significance
threshold were analyzed for MYC and RUNX consensus
binding motifs using a public domain toolset (http://
opossum.cisreg.ca/oPOSSUM3/; Figure 2A). This analy-
sis revealed a highly significant enrichment of canonical
MYC sites within 1 kb upstream and 500 bp downstream
of the promoters of upregulated genes, but not in the
downregulated set. Similar enrichment was also noted at
up to 10 kb from the target promoters, consistent with
evidence that overexpressed MYC can regulate by
enhancer “invasion” as well as by direct action at the
promoter.23 In contrast, RUNX motifs were enriched near
the promoters of the downregulated set and distal to
promoters of the upregulated set. Intriguingly, anchored
combination site analysis revealed enrichment of closely
linked MYC and RUNX sites near the promoters of a
subset of both up‐ and downregulated gene sets. Taken
together, these observations suggest a dual role for MYC
and RUNX in the regulation of both independent and
overlapping gene sets, with potential direct coregulation
FIGURE 1 Transcriptome analysis of premalignant thymus in CD2‐RUNX2/CD2‐MYC mice. A, Summary of key features of the
transgenic mouse models, as previously published.6,18 Top panel: Table showing the relative frequency and time of onset of T‐cell lymphoma
in CD2‐RUNX2/CD2‐MYC and parental mouse strains; bottom panel: schematic of 10‐day‐old RUNX2/MYC transgenic thymus showing
polyclonal immunoblasts (colored) alongside phenotypically normal lymphocytes (gray).18 B, Principal Component Analysis (PCA) plot of
microarray expression data, comparing 10‐day‐old thymus from WT and RUNX2/MYC mice (blue and red spheres, respectively).
C, Heatmaps showing the top 50 up‐ and downregulated genes ranked by significance. Shown are replicates for WT control and transgenic
RUNX2/MYC samples (C and R2/M, respectively). D, Bar plot showing the proportion of probes that are up‐ or downregulated using the
significance thresholds shown. The numbers above the bars indicate the total number of significant changes for each threshold
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of a critical subset. Although this analysis would not
detect long‐range cis interactions or non‐DNA binding
interactions, it indicates that direct DNA binding
interactions play a significant role in their oncogenic
collaboration. The genes and locations of relevant motifs
scored in the anchored transcription factor site analysis is
presented in Table S2.
As shown in Figure 2B, analysis by the DAVID
functional annotation tool26 (https://david.ncifcrf.gov/
home.jsp) also revealed a striking difference between
the up‐ and downregulated genes, as only the former
displayed highly significant enrichment for cell growth
and metabolic processes typically associated with MYC
overexpression.27 The downregulated set revealed
much less potent enrichment and favored gene
ontology terms indicative of cell surface and secreted
components. Intriguingly, this enrichment of surface
and signaling molecules resembles the pattern we
previously observed in fibroblasts over‐expressing Runx
genes, albeit with little overlap between the target gene
lists.28 These observations mirror the binding site
enrichment data and suggest that MYC drives a major
component of the upregulated gene expression,
whereas a subset of activated and repressed genes
may be subject to dual control.
3.2 | Perturbation of T‐cell signaling in
premalignant MYC/RUNX2 thymus
We next analyzed the altered gene set and their associated
fold‐changes in expression using Ingenuity Pathway
Analysis. Predicted upstream regulators of the altered gene
sets provide the strongest scores for MYC and the related
MYCN, both by P value of overlap and the activation
z‐score. Figure 2C lists the top ten upstream regulators,
ranked by activation score, as well as TP53 for comparison.
FIGURE 2 The functional analysis of transcriptomic changes in pre‐lymphomatous mouse thymus. A, The oPOSSUM analysis of
RUNX and MYC binding sites. Left panel: Consensus binding sites for RUNX and MYC used in the analysis. Right panel: Table showing the
percentage of RUNX, MYC, or RUNX+MYC binding sites found adjacent to the up‐ or downregulated genes (Proximal, defined as 1 kb
upstream and 500 bp downstream of the promoter) or in the upstream promoter region (defined as up to 10 kb upstream or downstream of
the promoter region). Significance is indicated with Z‐score, with those in red showing enrichment and those in blue showing fewer sites
than expected. B, DAVID Gene Ontology analysis of the genes that are up‐ and downregulated in control vs RUNX2/MYC transgenic mouse
thymus, showing the functional annotations that are most enriched. C, The top predicted upstream regulators of genes significantly changed
in 10‐day RUNX2/MYC transgenic thymus (Ingenuity IPA). Significance is indicated using Z‐score. Predicted activation or inhibition states
(red or blue bars, respectively) are as indicated. D, Weighted Venn diagram showing the overlap of the gene sets regulated by the top
upstream regulators noted in panel C
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A strong bias towards T‐cell signaling
pathways was evident from the positive activation state of
TCR, CD3, and CD28 coreceptor pathways, whereas the
most potently inhibited regulator was RICTOR (a
component of mTORC2). Although there was strong
overlap between the gene sets denoting CD3 and CD28
activation, these appeared largely distinct from MYC
activation and RICTOR inhibition, suggesting that these
are functionally distinct aspects of the MYC/RUNX2
oncogenic program (Figure 2D). Downregulation of
RICTOR‐dependent processes appears somewhat counter‐
intuitive in light of the association of RICTOR with growth
signaling. However, loss of RICTOR has been reported to
remove a block to T‐cell proliferation because of limiting
arginine and leucine levels,29 suggesting that MYC/RUNX2
collaboration may also entail loss of this critical metabolic
checkpoint. Strongly inhibitory states were also inferred for
CST5 (cystatin D) and the growth inhibitory microRNAs
let‐7 and miR‐16‐5p. These upstream regulators each have
functional links to p53.30-32 However, despite a strong
P value overlap indicating p53 as an upstream regulator of
the altered gene set, the activation state of p53 itself was
ambiguous with a majority of targets indicating inhibition
but a substantial minority denoting activation (Figure 2C).
The evidence for activation of pathways downstream of
TCR/CD3 is interesting as although RUNX2/MYC 10‐day
thymus shows marked upregulation of surface TCRαβ and
CD3, the aberrant population of CD8+ blast cells also occurs
in TCRα deficient mice, arguing that this expansion is
independent of TCR ligation.18 Moreover, stimulation of
immature thymocytes through CD3 or activation of MYC
normally leads to death by apoptosis as a sequel to activation
and proliferation,33,34 whereas RUNX2/MYC thymocytes
proliferate with a remarkably low apoptotic index.18 These
observations imply that the normal self‐limiting processes
that follow CD3 stimulation or MYC activation are not
TABLE 1 Discordantly regulated gene targets of top upstream regulators
Details of the genes discordantly regulated by the stated upstream regulators, as determined by the Ingenuity IPA analysis and noted in Table S3. For each gene,
the observed and expected state is shown to be either activated (red) or inhibited (blue). The number of Runx (R) or Myc (M) binding sites located proximal or
distal to the promoter region, as stated, determined by oPOSSUM‐3 analysis, are shown for each gene. The absence of a numeral indicates no sites were found.
The full names and relevant functions of the genes are shown.
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functional in these cells. For clues to the basis of this
phenomenon, we focused on the small set of target genes
that were regulated in the opposite manner from expected in
response to TCR/CD3 and MYC by pathway analysis
(highlighted in yellow in Table S3).
As shown in Table 1, a total of 24 unique genes were
regulated in a manner discordant with the overall prediction
of pathway activation for the top upstream regulators MYC,
TCR, CD3, and CD28. These genes were also significantly
enriched for MYC and RUNX binding motifs and for closely
linked sites both proximal and distal to the promoter regions.
Several genes were discordant for multiple regulators,
including Tnfrsf8/CD30, Ly6a/Sca1, Il13, and Cish. These
are strong candidates for dual regulation by MYC and
RUNX2 to abolish normal regulatory constraints on activa-
tion and proliferation.
FIGURE 3 Pathways altered in RUNX2/MYC transgenic thymus. A, Network diagram showing MYC‐regulated pathways altered in
RUNX2/MYC thymus, adapted from Ingenuity IPA. Shown are genes with predicted activation (red) or inhibition (blue), with darker colors
indicating higher confidence. Red arrow: predicted to lead to activation; blue arrow: predicted to lead to inhibition; gray arrows: no
prediction; yellow arrow: the measured findings are inconsistent with the activation state of the downstream molecule. B, Venn diagram
showing the interaction between gene sets with either MYC as an upstream regulator (activating) or p53 as an upstream regulator (activating
or inhibiting). Bold italics denotes genes with anchored RUNX/MYC binding sites. C, Scatterplot showing the expression of all genes (light
blue) and known p53 targets (dark blue)35 in WT and RUNX2/MYC thymus (Control and R2/M, respectively). p53 is highlighted in red. A
fold‐change of 1 (no change) is depicted by a solid gray line, whereas fold‐changes of +/− 1.4 are shown as dashed lines. D, Plot showing the
fold‐change in expression of p53 modifying enzymes in RUNX2/MYC thymus. Enzymes conferring inhibiting modifications (blue) and
activating modifications (green) are shown. The light blue modifiers are those that are significantly altered. Bold indicates the presence of
anchored RUNX/MYC binding sites
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3.3 | Analysis of p53 and target genes in
RUNX2/MYC thymus provides evidence of
functional attenuation
The ambiguous activation state of p53 in RUNX2/MYC
thymus is graphically illustrated by the IPA mechanistic
network function (Figure 3A), which showed discrepancies
with regard to the expected response of TP53 to MYC
activation and expression of the p53 downstream target
CDKN2A (yellow lines). Discordant observations were also
evident for cytokine signaling through STAT5A. Notably, p53
itself was observed to be overexpressed at the transcriptional
level whereas most of its activation targets were expressed at
similar levels to control, as shown in the scatterplot in Figure
3B. These observations rule out simple transcriptional
repression of p53 as the basis for its aberrant functional
readouts.
Inspection of the genes denoting p53 inhibition by IPA
showed a total of 46 genes, 41 of which were upregulated in
contrast to pathway prediction, whereas five were down-
regulated (Figure 3C and Table S3). Fourteen of the
upregulated genes were also annotated MYC activation
targets, in contrast to none of the downregulated genes,
suggesting that their overexpression in this context is the
result of a dominant MYC effect on transcriptional
upregulation (Table S3). The downregulated genes included
Ly6a/Sca‐1 and Gzmb, which overlap with the discordant
sets for MYC and CD3/TCR. Over‐representation of MYC
and RUNX motifs was again evident in the p53 inhibited set,
and functionally relevant targets with closely linked sites for
MYC and RUNX included Cdk4, Xpo1, and Ybx1 (bold
italics in Figure 3C). The full gene set and their relevant
functions are detailed in Table S4. The possibility that the
FIGURE 4 Smyd2 protein expression and inhibition. A, Total protein was extracted from day 10 thymus tissue derived from WT and
CD2‐Runx2/CD2‐Myc (GIM) transgenic mice, as indicated, and equivalent concentrations probed against antibodies to p53, p21WAF1, p19Arf
and Smyd2 (upper panel). Actin was used as an internal loading control for quantification of Smyd2 (bar chart, lower panel). Positive and
negative controls used for p19Arf detection were SV3T3 and NIH3T3 cell extracts, respectively. B, Western Blot analysis as in A using protein
extracts prepared from tumors (T) or tumor‐derived cell lines (C) from CD2‐Runx2/CD2‐Myc animals. Blots were probed against antibodies
to p53 and p19Arf. C, Metabolic inhibition of cell lines derived from Runx2/Myc/p53+/− mice (GIMP, as shown), as measured using the
CellTiter‐Glo assay. Upper and lower panels depict changes in cell viability following treatment with LLY‐507 or BAY‐598, respectively, at
the indicated concentrations
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overexpressed p53 is controlled at the posttranslational level
was also investigated, and all annotated modifiers of p53
were analyzed for transcriptional status in RUNX2/MYC
thymus. As shown in outline in Figure 3D and in detail in
Table S5, there was a preponderance of upregulation of p53‐
modifying enzymes over downregulation, and altered genes
included both activators and repressors of p53, showing that
competing influences impinge on p53 in the milieu of
nascent thymic lymphoma. However, only three genes
passed the q=<0.05 significance bar and all are posttransla-
tional inhibitors of p53. The greatest fold‐change affected
Smyd2, which encodes a lysine methyl transferase that
suppresses p53 trans‐activation by monomethylation (at
residue K370 in human p53).36 SMYD2 has been implicated
as a target for copy number gain and overexpression in
numerous cancer types37 and has been shown to be required
for MLL‐AF9 leukemia mouse models where RUNX
functions have also been implicated.38,39 Moreover, interest
in SMYD2 as a potential oncogenic driver has led to the
identification of several small molecule inhibitors,40-42
making this an attractive target for further investigation.
3.4 | Protein expression analysis of
RUNX2/MYC 10‐day thymus validates
SMYD2 and p53 target gene expression
status
Western blot analysis of cells extracted from 10‐day‐old
RUNX2/MYC mouse thymus (n= 3) compared with con-
trols confirmed that SMYD2 is overexpressed at the protein
level (Figure 4A). This analysis also confirmed that p53
protein levels were at least as high as controls, although one
sample displayed evidence of higher molecular weight forms
suggestive of posttranslational modification. Significantly,
expression of p21Waf1, a major downstream effector of p53
growth arrest, was not elevated, and was lower than two of
three control samples. However, expression of p19Arf, a target
of feedback repression by p53 43 was not observed in thymus.
As reported previously18 and shown in Figure 4B, high
expression of p19Arf in RUNX2/MYC/p53+/− lymphoma
lines that rapidly lose the wild‐type allele and p53 protein
expression on establishment in vitro argues strongly that
aberrant in vivo activity is not because of direct mutation of
either p19Arf or p53.
3.5 | RUNX2/MYC/p53−/− lymphoma
cell lines are insensitive to small molecule
SMYD2 inhibitor BAY‐598
Several specific inhibitors of SMYD2 have been identified
by screening small molecule inhibitor libraries. These are
chemically diverse but act as substrate competitive
inhibitors, inhibiting p53 monomethylation in vitro.44
Our initial studies with the lead compound AZ50545
showed no discernible activity against RUNX2/MYC
lymphoma lines but were not available to us for in vivo
use. We therefore tested more potent compounds, LLY‐
50742 and BAY‐586.40 As shown in Figure 4C, only LLY‐
507 induced significant metabolic inhibition as measured
by CellTiter‐Glo assay, and this was at a relatively high
concentration (0.5‐1 μM) compared with the reported
IC50 for p53 methylation. The other compound, BAY‐598,
displayed no obvious toxicity. During our study, a report
was published highlighting the off‐target effects of LLY‐
507 and the dispensability of both SMYD2 and SMYD3
for the viability and proliferation of a large series of
cancer cell lines.44 Our findings are in accord with this
study but do not exclude a role for SMYD2 in vivo or
under stress conditions.46
3.6 | SMYD2 blocks RUNX‐induced
SLGA in primary fibroblasts
The oncogenic potential of Runx gene overexpression is
constrained in normal cells by SLGA, a process that
entails upregulation of p19Arf/p53 and p16Cdkn2a, and
requires genetic integrity of both the p53 and Rb
pathways.11-14 To explore the potential of SMYD2 to
abrogate this response, a cDNA encompassing the
complete coding sequence was cloned into the MIGR1
expression vector and transfected into primary MEFs. As
all three Runx genes elicit an indistinguishable SLGA
phenotype, we analyzed the effects of Smyd2 on Runx1,
the most thoroughly analyzed family member.14 For
comparison, the effects of the methyltransferase Smyd5
were also investigated. As expected, Runx1 induced
SLGA in MEFs (Figure 5A). Notably, although Smyd5
had little effect on SLGA in MEFs, Smyd2 expression
both rescued the growth arrest induced by Runx1 in
MEFs (Figure 5B) and blocked SLGA as indicated by the
expression of SA‐β‐gal (Figure 5C), suggesting a specific
role for this enzyme.
4 | DISCUSSION
This study sheds light on the extremely potent synergy of
Runx and Myc family genes in lymphomagenesis and the
ability of this oncogene combination to counteract tumor
suppressor responses. In silico analysis reveals pathways
underlying the aberrant proliferation and survival of
nascent lymphoma cells, and identifies genes likely to be
involved in the subversion of failsafe processes that
precede rapid onset lymphomagenesis.18 As MYC and
RUNX overexpression have been implicated in a wide
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range of malignancies, these observations may be of wide
relevance to cancer.9
The analysis of significant gene expression changes in
premalignant RUNX2/MYC thymus revealed a strong
preponderance of gene upregulation over downregula-
tion, recapitulating the observations that fueled contro-
versy on the role of Myc as a “universal amplifier” 23 or
an on/off switch of gene expression.24,25 As the upregu-
lated genes with Myc signatures displayed much greater
fold‐changes, it is understandable that the role of Myc, as
a negative regulator, is obscured by the application of
standard significance thresholds. Although in silico
analysis of canonical MYC and RUNX binding sites
identifies only a subset of targets, potent enrichment of
MYC motifs in the promoters of altered genes indicates
that a substantial number are under direct control. As
enrichment is also observed up to 10 kb away, it appears
that MYC expression under CD2 LCR control leads to
enhancer “invasion” as reported in other overexpression
systems.24,25 In contrast, previous transcriptomic analysis
of target genes responding to ectopic RUNX1, 2, and 3
expression showed a common program with a balance
between positive and negative regulation of target gene
expression, reflecting the ability of these regulators to
recruit activating or repressive complexes in different
chromatin and cellular contexts.28,47 Moreover, Runx
factors operate on distal enhancer and silencer ele-
ments48,49 and can regulate gene expression through
effects on chromatin structure that do not require stable
binding.50 In this study the downregulated gene set
displayed enrichment of RUNX but not MYC motifs,
suggesting that RUNX2 is the principal “off‐switch” for
this gene set. Of particular interest was the enrichment of
closely linked MYC and RUNX motifs in a subset of both
positively and negatively regulated genes, identifying
candidate genes for dual control.
This analysis also illuminates earlier observations on
the interplay between ectopic MYC and RUNX
FIGURE 5 The effect of Smyd2 on
Runx1‐induced SLGA. A, Primary MEFs
were transduced with either a vector
containing Runx1 or the pBabe‐PURO
control, then SA‐β‐gal staining was
performed after 8 days in culture (left and
center panels). Parallel plates were
harvested at the same time and cell
extracts analyzed for p53, p21WAF1, and
p19Arf protein expression (right panel).
B, Growth curves for fibroblasts
transduced with Smyd2 or Smyd5, with or
without Runx1, as indicated. C, SA‐β‐Gal
staining of fibroblasts transduced with
Smyd2 or Smyd5, with or without Runx1,
as indicated. MEFs, murine embryo
fibroblasts; SLGA, senescence‐like growth
arrest
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expression in T‐cell development and the processes of
positive and negative selection of T‐cells which are
normally spatially and temporally separated in the
thymus.51 We showed previously that CD2‐RUNX2
transgenic mice display aberrant survival of a small
population of immature CD8 ISP cells undergoing
β‐selection that would normally be destined for “death
by neglect”.10 In contrast, MYC overexpression enhances
thymic positive selection while also priming cells for
apoptosis.33 A similar functional relationship has been
observed in vitro in T‐cell hybridomas that undergo
apoptosis after CD3/TCR activation, a process that
requires endogenous MYC/MAX activity 52 but is blocked
by ectopic RUNX expression.53 We suggest that the
potency of MYC/RUNX collaboration in lymphomagen-
esis reflects the ability of this oncogene combination to
simulate successful transit of cells through repertoire
selection while blocking the processes that limit
unscheduled proliferation. A “simulation” model appears
most likely as the early expansion and blast cell
phenotype observed in vivo occurs on a TCRα‐deficient
background.18
In light of these prior observations, the strong IPA
prediction of CD3/TCR and CD28 as upstream regulators
of the aberrant gene expression program in premalignant
RUNX2/MYC thymus in this study sheds light on the
likely targets involved. Moreover, a search among
discordantly regulated genes downstream of CD3/TCR
and MYC for those potentially coregulated by MYC and
RUNX revealed a number of targets with the potential to
account for the failure of CD3/MYC‐mediated apoptosis,
including Tnfrs8/CD30,54 Interleukin‐1355 and the SOCS
family member Cish.56 Although the functional analysis
is beyond the scope of this study, it would be of great
interest to examine the roles of these targets in
lymphoma development in vivo.
The expression of Trp53 mRNA is significantly
elevated in RUNX2/MYC thymus, and we noted modest
overexpression of p53 protein compared with control
thymus from age‐matched mice. The fact that p53
activation targets are largely unaffected despite the
expression of two p53 agonists (RUNX2 and MYC)
whereas the p53‐p19Arf feedback loop43 remains intact
argues that the p53 response is controlled at the
posttranscriptional level in premalignant cells.
Transcriptome analysis of premalignant RUNX2/
MYC thymus for genes encoding known posttransla-
tional modifiers of p53 revealed three inhibitory
factors that were significantly upregulated. The most
highly upregulated was Smyd2, a gene encoding a
lysine methyltransferase that has been associated
with poor prognosis in a wide range of leukemias
and solid tumors37,57-60 and has been targeted for drug
development.40,41,45 Our results confirm recent find-
ings that the reported SMYD2 inhibitors behave
discordantly because of off‐target effects, and the
resistance of RUNX2/MYC cell lines to specific
inhibitors recapitulates a wider CRISPR‐Cas study of
cancer cell lines.44 However, RUNX2/MYC lines show
consistent deletion of p53, whereas primary tumors
and transplanted lymphomas often retain the wild‐
type allele,18 arguing that in vivo and in vitro growth
selection are markedly different processes. Moreover,
as SMYD2 inhibition is synergistic with genotoxic
stress40,46 it is possible that in tumor cell lines loss of
tumor suppressor function and benign culture condi-
tions allow survival without functional SMYD2.
RUNX overexpression in primary fibroblasts induces
senescence‐like growth arrest in a p53‐ and p16‐
dependent manner,12-14 and our observation that
ectopic SMYD2 can rescue cells from this process
provides support for a role in cells with intact tumor
suppressor pathways. Moreover, the observation that
Smyd2 knockout prevents development of MLL‐AF9
leukemia in a mouse model38 reveals an essential role
in at least some cancer types, whereas the require-
ment of MLL leukemias for the RUNX gene activity
suggests a functional link to the present findings.61,62
Although beyond the scope of this study, in future it
will be interesting to test the sensitivity of primary
RUNX2/MYC lymphomas to the loss of SMYD2
function in vivo.
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